Radiolabel ADME (Absorption, Distribution, Metabolism, and Excretion) Study Of [14C] PF-00868554 In Healthy Adult Male Subjects

Pfizer

Status and phase: Completed; Phase 1

Conditions: HCV

Treatments: Drug: [14C]-PF-00868554

Study type: Interventional

Funder types: Industry

Identifiers

NCT00823745

A8121013

Details and patient eligibility

About

This is a phase 1 study to assess the routes of elimination of a single oral dose of [14C] PF-00868554 and to characterize the metabolic profile following single dose administration.

Enrollment: 7 patients

Sex: Male

Ages: 18 to 45 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Male, healthy volunteers.

Exclusion criteria

• Females.

Trial design

Primary purpose: Basic Science

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

7 participants in 1 patient group

1

Experimental group

Description:

\[14C\]-PF-00868554

Treatment:

Drug: [14C]-PF-00868554